Straits Times Index
3,302.11 -1.08 (-0.03%) Nikkei
38,835.10 +599.03 (+1.57%) Hang Seng
18,485.91 -92.39 (-0.50%) FTSE 100
8,310.17 +96.68 (+1.18%) Bitcoin USD
63,660.57 -547.38 (-0.85%) CMC Crypto 200
1,368.33 +3.20 (+0.23%)
Hanall Biopharma Co., Ltd. (009420.KS)
| Previous close | 35,250.00 |
| Open | 35,900.00 |
| Bid | 35,800.00 x 0 |
| Ask | 35,900.00 x 0 |
| Day's range | 35,500.00 - 36,400.00 |
| 52-week range | 18,400.00 - 46,750.00 |
| Volume | |
| Avg. volume | 606,524 |
| Market cap | 1.817T |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 43,000.00 |
PR NewswireHanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, announced the initiation of a Phase III VELOS-4 trial evaluating the efficacy and safety of tanfanercept, a novel, topical anti-inflammatory treatment in participants with moderate to severe dry eye disease (DED).
- PR Newswire
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for first quarter 2024 and provided business updates.
- PR Newswire
HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for 2023 and provided business updates.
